[go: up one dir, main page]

ES2039236T3 - Metodo para preparar una composicion terapeutica de interlenquina-2 y/o interferon-beta y factor de necrosis tumoral. - Google Patents

Metodo para preparar una composicion terapeutica de interlenquina-2 y/o interferon-beta y factor de necrosis tumoral.

Info

Publication number
ES2039236T3
ES2039236T3 ES198787303120T ES87303120T ES2039236T3 ES 2039236 T3 ES2039236 T3 ES 2039236T3 ES 198787303120 T ES198787303120 T ES 198787303120T ES 87303120 T ES87303120 T ES 87303120T ES 2039236 T3 ES2039236 T3 ES 2039236T3
Authority
ES
Spain
Prior art keywords
beta
tnf
interlenquine
interferon
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198787303120T
Other languages
English (en)
Inventor
Jeffrey Lee Winkelhake
Robert Zimmerman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Cetus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetus Corp filed Critical Cetus Corp
Application granted granted Critical
Publication of ES2039236T3 publication Critical patent/ES2039236T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE PUEDE AUMENTAR LA ACTIVIDAD ANTITUMORAL EN MAMIFEROS ADMINISTRANDO AL HUESPED MAMIFERO UNA CANTIDAD EFICAZ DE TNF E IL-2 O DE TNF E IFN-(BETA) O DE TNF, IL-2 E IFN-(BETA) EN COMBINACION. LA COMPOSICION DE TNF E IL-2 Y/O IFN-(BETA) SE PUEDE PREPARAR IN VITRO O ADMINISTRAR SEPARADAMENTE AL HUESPED. SI EL TNF E IL-2 SE ADMINISTRAN SECUENCIALMENTE, EL TNF TIENE QUE ADMINISTRARSE ANTES QUE EL IL-2 PARA CONSEGUIR SINERGIA. LA COMPOSICION ES UTIL PARA TRATAR CANCERES, TALES COMO MASTOCITOMA, MELANOMA, LEUCEMIA Y LINFOMA.
ES198787303120T 1986-04-09 1987-04-09 Metodo para preparar una composicion terapeutica de interlenquina-2 y/o interferon-beta y factor de necrosis tumoral. Expired - Lifetime ES2039236T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84971386A 1986-04-09 1986-04-09
US88454886A 1986-07-11 1986-07-11
US94360886A 1986-12-18 1986-12-18

Publications (1)

Publication Number Publication Date
ES2039236T3 true ES2039236T3 (es) 1993-09-16

Family

ID=27420340

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198787303120T Expired - Lifetime ES2039236T3 (es) 1986-04-09 1987-04-09 Metodo para preparar una composicion terapeutica de interlenquina-2 y/o interferon-beta y factor de necrosis tumoral.

Country Status (10)

Country Link
EP (1) EP0248516B1 (es)
JP (1) JP2528114B2 (es)
AU (1) AU608509B2 (es)
CA (1) CA1290249C (es)
DE (1) DE3771584D1 (es)
DK (1) DK182387A (es)
ES (1) ES2039236T3 (es)
FI (1) FI871545A7 (es)
GR (1) GR3002779T3 (es)
IL (1) IL82143A (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL80005A (en) * 1986-09-10 1992-11-15 Yeda Res & Dev Compositions for modulating the effect of tnf and il-1
SE8701004D0 (sv) * 1987-03-11 1987-03-11 Astra Ab Method for therapy of leukemias and certain other malignancies
WO1989007445A1 (en) * 1988-02-11 1989-08-24 Board Of Regents, The University Of Texas System Improved method for treatment of cancer with activated oncolytic leukocytes
GB2230440B (en) * 1989-02-09 1993-05-19 Sandoz Ltd Novel cyclosporin galenic forms
GB2260902A (en) * 1991-09-12 1993-05-05 Eurocetus Bv Interleukin-2 and tumour necrosis factor for treating bladder cancer
DE19544167A1 (de) * 1995-11-17 1997-05-22 Schering Ag Verwendung von Interferon-ß zur Behandlung von Bronchialkarzinom bei Bestrahlungstherapie
SI1471974T1 (sl) * 2002-02-06 2007-12-31 Ares Trading Sa Tumorje nekrotizirajoäśi faktor, kombiniran z interferonom, pri demielinizirajoäśih boleznih
US12421502B2 (en) 2013-04-18 2025-09-23 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy
WO2014170389A1 (en) * 2013-04-18 2014-10-23 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy
IL322309A (en) 2017-05-24 2025-09-01 Novartis Ag IL2 antibody grafted proteins and methods of use in cancer treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1265444A (en) * 1983-06-27 1990-02-06 Lloyd J. Old Effect of human tumor necrosis factor and human interferon on human cancer cells and methods
EP0149551A3 (en) * 1984-01-16 1987-09-23 Genentech, Inc. Gamma interferon-interleukin-2 synergistic compositions and processes therefor
EP0158487B1 (en) * 1984-04-09 1991-08-28 Takeda Chemical Industries, Ltd. Stable composition of interleukin-2
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
NZ219027A (en) * 1986-01-24 1989-09-27 Genentech Inc Antiviral composition containing interferon tumour necrosis factor and/or lymphotoxin

Also Published As

Publication number Publication date
FI871545A0 (fi) 1987-04-08
EP0248516A1 (en) 1987-12-09
GR3002779T3 (en) 1993-01-25
JPS62242629A (ja) 1987-10-23
EP0248516B1 (en) 1991-07-24
FI871545L (fi) 1987-10-10
DK182387A (da) 1987-10-10
CA1290249C (en) 1991-10-08
JP2528114B2 (ja) 1996-08-28
AU608509B2 (en) 1991-04-11
AU7117687A (en) 1987-10-15
FI871545A7 (fi) 1987-10-10
DK182387D0 (da) 1987-04-09
IL82143A (en) 1992-07-15
IL82143A0 (en) 1987-10-30
DE3771584D1 (de) 1991-08-29

Similar Documents

Publication Publication Date Title
ES2074867T3 (es) Derivados de quinazolina para potenciar la actividad antitumoral.
ES8708235A1 (es) Un procedimiento para la preparacion de derivados de androstendiona 4-sustituida
ES2039236T3 (es) Metodo para preparar una composicion terapeutica de interlenquina-2 y/o interferon-beta y factor de necrosis tumoral.
IL69731A0 (en) Homogeneous human interleukin 2,its preparation and pharmaceutical compositions containing it
NO852673L (no) Tumor-nekrosefaktor.
ES2147780T3 (es) Compuestos sinteticos afines al extracto de corteza de roble, y procedimiento para utilizar los mismos.
UA29466C2 (uk) Фармацевтична композиція з антипухлинною активністю
ES2087163T3 (es) Preparacion antitumoral que comprende intreleucina-2 e histamina, analogo al de las mismas o agonistas de receptor h2.
Liang et al. The effects of recombinant human granulocyte colony-stimulating factor mouthwash on radiotherapy-induced oral mucositis in locally advanced nasopharyngeal carcinoma patients
MX9204077A (es) Estimulacion anti-cd3 a corto plazo de linfocitos para incrementar su actividad in vivo.
EP0231819A3 (en) Pharmaceutical agent for the treatment of myelogenous leukemia
DE69734574D1 (de) Rekombinante adenovirenvektoren zur gentherapie der menschlichen krebse
ATE157544T1 (de) Verwendung von human-beta-interferon zur stimulierung der erythropoiesis
ES2068714T3 (es) Derivados de pirimidina para aumentar la actividad antitumoral.
ES2036526T3 (es) Composiciones de interferon.
GR3001375T3 (en) Enhancement of prazosin
ES2187799T3 (es) Complejos de bis-platino con derivados de polimetileno como ligandos que tienen actividad antitumoral.
KR950700684A (ko) 시클릭 항-종양 촉진제 화합물, 그의 조성물, 제조 방법 및 용도(Cyclic Anti-Tumor Promoter Compounds, Compositions and Methods for Production and Use)
KR960700734A (ko) 사람 암에 대한 시스플래틴/타목시펜 배합 치료(Combination cisplatin/tamoxifen therapy for human cancers)
EP0295559A3 (en) Pharmaceutical composition for the treatment of tumors
ES2061496T3 (es) Tratamiento intralesional del carcinoma de celulas basales con alfa-interferon humano recombinante.
ES2164011B1 (es) Uso combinado de la quimiocina ip-10 y la interleucina-12 en la preparacion de composiciones para el tratamiento de tumores malignos.
Sosnowski et al. Treatment of murine transitional cell carcinoma with intralesional interleukin 2 and murine interferon gamma
Sato et al. Induction of bone formation in an adenoid cystic carcinoma of the maxillary sinus by adoptive immunotherapy involving intra-arterial injection of lymphokine-activated killer cells and recombinant interleukin-2 in combination with radiotherapy
ATE130194T1 (de) Subkutane verabreichung des humanen choriongonadotropins.